Evidence map›Paper›PMID 39611709›Full record

ArticleNanomedicine (London, England)2025

Ultrasmall solid lipid nanoparticles as a potential innovative delivery system for a drug combination against glioma.

Luigi Battaglia, Chiara Dianzani, Elisabetta Muntoni, Elisabetta Marini, Annalisa Bozza, Valentina Bordano, Chiara Ferraris, Sara Garelli, Maria Carmen Valsania, Enzo Terreno and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Luigi BattagliaDepartment of Drug Science and Technology, University of Turin, Turin, Italy.
Chiara DianzaniDepartment of Drug Science and Technology, University of Turin, Turin, Italy.
Elisabetta MuntoniDepartment of Drug Science and Technology, University of Turin, Turin, Italy.
Elisabetta MariniDepartment of Drug Science and Technology, University of Turin, Turin, Italy.
Annalisa BozzaDepartment of Drug Science and Technology, University of Turin, Turin, Italy.
Valentina BordanoDepartment of Drug Science and Technology, University of Turin, Turin, Italy.
Chiara FerrarisDepartment of Drug Science and Technology, University of Turin, Turin, Italy.
Sara GarelliDepartment of Drug Science and Technology, University of Turin, Turin, Italy.
Maria Carmen ValsaniaNanostructured Interfaces and Surfaces (NIS) Interdepartmental Centre, University of Turin, Turin, Italy.
Enzo TerrenoMolecular & Preclinical Imaging Centers, Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.
Martina CapozzaMolecular & Preclinical Imaging Centers, Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.
Diana CostanzoMolecular & Preclinical Imaging Centers, Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.
Maria Teresa CapucchioDepartment of Veterinary Sciences, University of Turin, Grugliasco, Italy.
Talal HassanDepartment of Veterinary Sciences, University of Turin, Grugliasco, Italy.
Stefania PizzimentiDepartment of Clinical and Biological Sciences, University of Turin, Turin, Italy.
Elisa PettineoDepartment of Clinical and Biological Sciences, University of Turin, Turin, Italy.
Maria Di MuroR Bio Transfer srl, Salerno, Italy.
Franco ScorzielloR Bio Transfer srl, Salerno, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHigh grade gliomas are characterized by a very poor prognosis due to fatal relapses after surgery. Current chemotherapy is only a palliative care, while potential drug candidates are limited by poor overcoming of the blood-brain barrier.

aimsA suitable chemotherapeutic approach should be engineered to overcome both the altered blood-brain barrier in the glioma site, as well as the intact one in the brain adjacent to tumor zone, and to target the multiple factors influencing glioma proliferation, differentiation, migration, and angiogenesis. MATERIALS &

methodsIn this experimental research, ultrasmall solid lipid nanoparticles were prepared owing to the temperature phase inversion technology and loaded with a specific drug combination made of paclitaxel, regorafenib, and nanoceria.

resultsSuch solid lipid nanoparticles demonstrated capability to inhibit glioma cell proliferation and migration, as well as angiogenesis

conclusionsThus, promising results for glioma treatment were obtained with a technology characterized by safety and economy, allowing the perspective of successful scalability.

Indexed as

Brain NeoplasmsCell ProliferationGliomaLipidsNanoparticlesPaclitaxelAnimalsBlood-Brain BarrierCell Line, TumorCell MovementDrug CarriersDrug Delivery SystemsHumansLiposomesParticle SizePhenylurea CompoundsDrug CarriersLipid NanoparticlesLipidsLiposomesPaclitaxelPhenylurea CompoundsPyridinesregorafenibantioxidantblood–brain barrierbrain tumorNanotechnologypaclitaxelregorafenib

Identifiers

PMID39611709
PMCPMC11703491

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.